Search Wegovy prices in Korea and you'll see two very different numbers, sitting in the same thread, contradicting each other. One post says the drug runs about 210,000 KRW a month. Another says 370,000 KRW, before doctor visits. Both can be true. They describe different stages of treatment — and that's the part the screenshots never explain.

In Korea, the conversation gets confusing because people quote the starting dose as if it were the long-term monthly cost. It isn't. If you're budgeting seriously, the only honest method is to look at the full dose ladder, then add the routine medical costs that sit around the prescription.

What Wegovy Is, and Why the Korean Price Feels So Scattered

Wegovy is semaglutide, a GLP-1 receptor agonist for chronic weight management. It launched in Korea in October 2024 and remains a self-pay treatment for most patients. There is no single neat insurance price that settles the question.

The number you hear depends on three things:

your current dose
the clinic and pharmacy route you're using
whether you mean the drug alone or the full monthly treatment cost

The gap between an early month and a maintenance month is large enough to distort the entire budget conversation.

Korea Dose-by-Dose Price Guide

The most practical way to read the market in 2026 is with a simple four-week working table:

Dose	Typical 4-Week Price	Treatment Stage
0.25 mg	about 210,000 KRW	starter dose
0.5 mg	about 230,000 KRW	first increase
1.0 mg	about 270,000 KRW	second increase
1.7 mg	about 320,000 KRW	third increase
2.4 mg	about 370,000 KRW	common maintenance dose

That's why the headline number matters. 210,000 KRW is what people remember because it sounds manageable. 370,000 KRW is the figure that usually matters once treatment is established.

If you're estimating life after the first few months, budget from the maintenance end, not the entry price. Month-three you, looking at the receipt, will be glad you did.

The most misleading Wegovy number in Korea is the starter-dose number. The month that feels manageable at the beginning is rarely the month that defines the long-term budget.

What One Month Really Costs

The drug price is only part of the story. For a patient already on 2.4 mg, a realistic monthly treatment budget in Korea often looks like this:

Wegovy pen: about 370,000 KRW
follow-up visit: about 30,000 to 50,000 KRW
periodic lab work: roughly 20,000 to 50,000 KRW when needed
small supplies: around 5,000 KRW

A maintenance month usually lands around 400,000 to 430,000 KRW, with higher totals in months that include blood tests or pricier consultation fees. Not the number on the pen alone — the number that actually leaves your account on the first of the month.

The first four months are cheaper because the dose is still climbing. Using the ladder above, medication for those four months totals roughly 1,030,000 KRW before visit and testing costs.

A First-Year Budget Map

Patients underestimate Wegovy because they think in single months instead of phases. The first year has two cost moods: the ramp-up months and the maintenance months.

Period	Typical Dose Focus	Drug Cost Picture	All-In Reality
Months 1-4	0.25 mg to 1.7 mg	Lower than maintenance	Usually easier to absorb psychologically
Month 5 onward	2.4 mg	About 370,000 KRW/month	Often 400,000 to 430,000 KRW/month after routine care
12-month view	Mixed	Depends on titration speed and clinic path	A meaningful annual self-pay commitment

That's why monthly screenshots from communities can be so misleading. A starter-month receipt isn't wrong. It just doesn't describe the phase that drives the long-term budget.

Wegovy vs. Mounjaro vs. Saxenda in Korea

Korean patients aren't choosing Wegovy in a vacuum anymore. The comparison points are clearer than a year ago.

Drug	Ingredient	How It Is Taken	Typical 4-Week Cost in Korea	Notes
Wegovy	semaglutide	weekly injection	about 370,000 KRW at 2.4 mg	once weekly, strong name recognition
Mounjaro	tirzepatide	weekly injection	about 278,000 KRW at 2.5 mg, 369,000 KRW at 5 mg	lower entry cost, strong efficacy profile
Saxenda	liraglutide	daily injection	roughly 280,000 to 600,000 KRW	older option, daily dosing burden

Mounjaro sharpens the Korean pricing conversation because it undercuts Wegovy at the starting dose and lands close to it around common maintenance dosing. Saxenda still looks cheaper in some settings, but the daily injections and weaker weight-loss profile change the value calculation for many patients.

What to Ask Before the First Prescription

The most useful questions are the least glamorous — and they're the ones nobody asks at the first visit because they sound boring.

What will my clinic charge for follow-up visits after the first month?
How often do you typically repeat blood work in the first year?
Under what circumstances would you hold a patient at 1.0 mg or 1.7 mg instead of pushing toward 2.4 mg?
If side effects appear, do you usually slow titration or switch drugs?
What part of the expected bill is paid to the clinic, and what part is paid separately to the pharmacy?

Patients who ask these early get fewer pricing surprises later. In Korea's self-pay environment, the structure around the prescription matters almost as much as the prescription itself.

Who Can Be Prescribed Wegovy in Korea

Wegovy is generally prescribed for adults who meet obesity-treatment criteria, typically:

BMI 30 or higher
BMI 27 or higher with a weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia

The usual flow is straightforward:

first consultation at an obesity clinic or endocrinology practice
weight, BMI, and medical history review
blood work when needed
start at 0.25 mg
increase gradually toward 2.4 mg if tolerated and clinically appropriate

That stepwise increase is why the first prescription price rarely tells you the long-term budget.

How to Keep the Cost From Drifting Up Further

No magic tricks, but a few sensible levers.

First, compare total self-pay quotes, not just the pen price. Some clinics look cheaper until consultation fees or add-on tests appear.

Second, ask your prescriber to judge the dose by response and tolerability, not momentum alone. Some patients stay longer at 1.0 mg or 1.7 mg if the weight trend is good and side effects are already meaningful.

Third, treat private insurance reimbursement as uncertain unless your policy clearly says otherwise. Coverage terms vary, and Wegovy in Korea still sits in a gray area for many patients. Worth checking, never assume.

Is Overseas Purchase a Real Option?

In practice, no.

Overseas sellers and informal channels carry three problems at once: authenticity risk, storage failures, and no follow-up if something goes wrong. With injectable semaglutide, cold-chain handling alone is reason enough not to treat unofficial import routes as a serious plan. A pen that sat warm in a non-refrigerated parcel for two days, somewhere on a runway in summer, is a pen you cannot trust.

If you're going to use Wegovy, the sensible route is still formal prescription and local follow-up.

Oral Wegovy Changes the Global Pricing Story, Not Korea's Current One

The most important new variable in 2026 is oral Wegovy in the United States. This matters for the broader GLP-1 market, even if it does not yet change what a Korean patient pays this month.

As of April 2026, the approved U.S. tablet strengths are:

1.5 mg
4 mg
9 mg
25 mg

Pricing is also more nuanced than older summaries suggest:

1.5 mg starts at about $149 per month
4 mg is $149 per month through April 15, 2026, then $199
higher doses are around $299 per month

Oral Wegovy sets a new price anchor for branded GLP-1 therapy. But in Korea, it's still a future variable rather than a present retail reality. Korean launch timing remains uncertain.

Oral Wegovy matters because it changes the price psychology of the whole category. It does not yet change what a Korean patient pays this week.

Bottom Line

The cleanest working number for Wegovy in Korea in 2026: once you're established on treatment, a month lands around 400,000 to 430,000 KRW after medication and routine care.

The cheaper starter price is real, but it's not the number most patients live with for long. Anchor on the maintenance dose, keep clinic fees in view, and assume Korea's GLP-1 market stays competitive as oral options and rival brands press on pricing.

One last practical point. In a self-pay market, annual planning matters more than headline pricing. A patient who thinks clearly about twelve months will make a better decision than one who fixates on the first receipt. Wegovy in Korea isn't an impulse purchase. It's a treatment commitment with a monthly footprint that shows up on every bank statement, right next to the rent.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All GLP-1 medications discussed are prescription drugs — do not start, stop, or change any medication without consulting your doctor. Individual results vary. For the most current prescribing information, refer to the FDA-approved labeling for each drug.